{"id":2941,"date":"2024-07-27T07:12:03","date_gmt":"2024-07-27T07:12:03","guid":{"rendered":"https:\/\/blogs.cardiff.ac.uk\/centre-for-trials-research\/?p=2941"},"modified":"2024-08-09T10:49:26","modified_gmt":"2024-08-09T10:49:26","slug":"pathos-clinical-trial-exploring-de-intensification-in-head-and-neck-cancer","status":"publish","type":"post","link":"https:\/\/blogs.cardiff.ac.uk\/centre-for-trials-research\/pathos-clinical-trial-exploring-de-intensification-in-head-and-neck-cancer\/","title":{"rendered":"PATHOS Clinical Trial: Exploring De-Intensification in Head and Neck Cancer"},"content":{"rendered":"

The PATHOS clinical trial<\/a> is investigating the potential benefits of de-intensified treatment for individuals with head and neck cancer, specifically HPV-positive oropharyngeal cancer. Led by Professors Terry Jones and Mererid Evans, the trial is funded by Cancer Research UK, co-sponsored by Cardiff University and Velindre University NHS Trust and managed by the Centre for Trials Research at Cardiff University.<\/p>\n

The recruitment target of 1,269 participants has been achieved, and we acknowledge the fantastic support from participants and sites.\u00a0 The study aims to compare the outcomes of less intensive treatment against standard treatment. The primary focus is on whether a reduced intensity approach can minimize swallowing difficulties without compromising the effectiveness of the treatment.<\/p>\n

All participants undergo surgery to remove their cancer, a procedure that remains consistent regardless of trial participation. Following surgery, a pathologist examines the cancer tissue under a microscope and identifies key features, such as the cancer stage, which help doctors determine the necessity and type of additional treatment.<\/p>\n

Participants in Group A do not require further treatment, but still have follow up visits with the trial team.<\/p>\n

Participants in Group B will have radiotherapy.<\/p>\n

\"\"<\/figure>\n

Participants in Group C will have radiotherapy alone or radiotherapy and chemotherapy.<\/p>\n

\"\"<\/figure>\n

The PATHOS trial represents a significant step towards optimizing cancer treatment by potentially reducing side effects while maintaining efficacy.<\/p>\n

Feedback from PATHOS Participants<\/strong><\/p>\n

A Cardiff dad-of-two who thanks research for saving his life has been chosen to launch\u00a0STAND UP TO CANCER<\/strong><\/em><\/a> in Wales. Read more at https:\/\/www.walesonline.co.uk\/news\/health\/painless-lump-mentioned-way-out-28427376<\/a><\/p>\n

\n

A throat cancer survivor says a pioneering clinical trial has “helped me get back to enjoying life with my wife”.<\/em><\/p>\n

Another participant reported\u00a0\u00a0 Taking part in the trial has “given me a lot more mental security” as he has been in hospital and “I’m constantly checked up on it”.\u00a0<\/em><\/p>\n

Read more at https:\/\/www.bbc.co.uk\/news\/articles\/c3g9j48n649o<\/a><\/em><\/p>\n<\/blockquote>\n

Another participant wrote to the study team with the following feedback:<\/p>\n

\n

After six years of following a lower dosage of radiotherapy, I am grateful to report that I can swallow normally, except for rare difficulties with very sticky foods, thanks to the dedication of a multidisciplinary team of health professionals. As an engineer, I found that seeing x-ray footage of my swallowing during the PATHOS study greatly enhanced my understanding of the importance of swallowing exercises, and I suggest that similar visual aids might help other patients comprehend and adhere to their exercises. <\/em><\/p>\n<\/blockquote>\n

The trial closes recruitment in October 2024, with results expected early 2028.\u00a0\u00a0 The study team is so grateful to all the sites and all the wonderful participants who have supported this trial.<\/p>\n","protected":false},"excerpt":{"rendered":"The PATHOS clinical trial is investigating the potential benefits of de-intensified treatment for individuals with head and neck cancer, specifically HPV-positive oropharyngeal cancer. Led by Professors Terry Jones and Mererid […]","protected":false},"author":7068,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_jetpack_newsletter_access":"","_jetpack_dont_email_post_to_subs":false,"_jetpack_newsletter_tier_id":0,"_jetpack_memberships_contains_paywalled_content":false,"_jetpack_feature_clip_id":0,"_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2},"jetpack_post_was_ever_published":false},"categories":[7],"tags":[],"class_list":["post-2941","post","type-post","status-publish","format-standard","hentry","category-events"],"jetpack_publicize_connections":[],"jetpack_sharing_enabled":true,"jetpack_shortlink":"https:\/\/wp.me\/p7dIou-Lr","jetpack-related-posts":[{"id":2693,"url":"https:\/\/blogs.cardiff.ac.uk\/centre-for-trials-research\/world-radiography-day-2023-centre-for-trials-research-radiotherapy-trials-and-beyond\/","url_meta":{"origin":2941,"position":0},"title":"World Radiography Day 2023: Centre For Trials Research Radiotherapy Trials And Beyond","author":"Sarah Bridges","date":"November 7, 2023","format":false,"excerpt":"Authors: Sarah Bridges, Christie Heiberg, Lisette Nixon, Jack Pritchard, Ann White BACKGROUND World Radiography Day marks the anniversary of the discovery of x-rays by Wilhelm Roentgen in 1895.\u00a0Soon after Roentgen\u2019s discovery, scientists began experimenting with x-rays on living tissue, learning that they were an effective method of stopping cancer cells\u2026","rel":"","context":"In "Events"","block_context":{"text":"Events","link":"https:\/\/blogs.cardiff.ac.uk\/centre-for-trials-research\/category\/events\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/blogs.cardiff.ac.uk\/centre-for-trials-research\/wp-content\/uploads\/sites\/499\/2023\/11\/RT-blog-pic-1.jpg?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/blogs.cardiff.ac.uk\/centre-for-trials-research\/wp-content\/uploads\/sites\/499\/2023\/11\/RT-blog-pic-1.jpg?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/blogs.cardiff.ac.uk\/centre-for-trials-research\/wp-content\/uploads\/sites\/499\/2023\/11\/RT-blog-pic-1.jpg?resize=525%2C300&ssl=1 1.5x, https:\/\/i0.wp.com\/blogs.cardiff.ac.uk\/centre-for-trials-research\/wp-content\/uploads\/sites\/499\/2023\/11\/RT-blog-pic-1.jpg?resize=700%2C400&ssl=1 2x, https:\/\/i0.wp.com\/blogs.cardiff.ac.uk\/centre-for-trials-research\/wp-content\/uploads\/sites\/499\/2023\/11\/RT-blog-pic-1.jpg?resize=1050%2C600&ssl=1 3x, https:\/\/i0.wp.com\/blogs.cardiff.ac.uk\/centre-for-trials-research\/wp-content\/uploads\/sites\/499\/2023\/11\/RT-blog-pic-1.jpg?resize=1400%2C800&ssl=1 4x"},"classes":[]},{"id":1885,"url":"https:\/\/blogs.cardiff.ac.uk\/centre-for-trials-research\/spotlight-on-the-pathos-study\/","url_meta":{"origin":2941,"position":1},"title":"Spotlight on: The PATHOS Study","author":"Richard Haggerty","date":"August 5, 2020","format":false,"excerpt":"PATHOS is a Phase III trial of risk-stratified, reduced intensity adjuvant treatment in patients undergoing transoral surgery for human papillomavirus (HPV)-positive oropharyngeal cancer. The aim of the study is to tailor treatment for participants with HPV-positive oropharyngeal cancer to reduce side-effects, particularly swallowing problems, which have a major impact on\u2026","rel":"","context":"In "Events"","block_context":{"text":"Events","link":"https:\/\/blogs.cardiff.ac.uk\/centre-for-trials-research\/category\/events\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/blogs.cardiff.ac.uk\/centre-for-trials-research\/wp-content\/uploads\/sites\/499\/2020\/08\/Pathos-logo.jpg?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/blogs.cardiff.ac.uk\/centre-for-trials-research\/wp-content\/uploads\/sites\/499\/2020\/08\/Pathos-logo.jpg?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/blogs.cardiff.ac.uk\/centre-for-trials-research\/wp-content\/uploads\/sites\/499\/2020\/08\/Pathos-logo.jpg?resize=525%2C300&ssl=1 1.5x, https:\/\/i0.wp.com\/blogs.cardiff.ac.uk\/centre-for-trials-research\/wp-content\/uploads\/sites\/499\/2020\/08\/Pathos-logo.jpg?resize=700%2C400&ssl=1 2x, https:\/\/i0.wp.com\/blogs.cardiff.ac.uk\/centre-for-trials-research\/wp-content\/uploads\/sites\/499\/2020\/08\/Pathos-logo.jpg?resize=1050%2C600&ssl=1 3x"},"classes":[]},{"id":2734,"url":"https:\/\/blogs.cardiff.ac.uk\/centre-for-trials-research\/faktion-and-the-breast-cancer-drug-paving-a-future-for-hormonal-therapies\/","url_meta":{"origin":2941,"position":2},"title":"FAKTION And The Breast Cancer Drug Paving A Future For Hormonal Therapies","author":"Margherita Carucci","date":"November 29, 2023","format":false,"excerpt":"- by Margherita Carucci and Angela Casbard on behalf of the FAKTION CTR Team When a patient is diagnosed with cancer, their doctor will prescribe a drug or a combination of drugs for destroying or keeping the cancer cells under control. But how do doctors know which drugs are the\u2026","rel":"","context":"In "Events"","block_context":{"text":"Events","link":"https:\/\/blogs.cardiff.ac.uk\/centre-for-trials-research\/category\/events\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/blogs.cardiff.ac.uk\/centre-for-trials-research\/wp-content\/uploads\/sites\/499\/2023\/11\/Breast-Cancer-Breakthrough-The-FAKTION-Trials-Pioneering-Findings-at-ASCO.jpg?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/blogs.cardiff.ac.uk\/centre-for-trials-research\/wp-content\/uploads\/sites\/499\/2023\/11\/Breast-Cancer-Breakthrough-The-FAKTION-Trials-Pioneering-Findings-at-ASCO.jpg?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/blogs.cardiff.ac.uk\/centre-for-trials-research\/wp-content\/uploads\/sites\/499\/2023\/11\/Breast-Cancer-Breakthrough-The-FAKTION-Trials-Pioneering-Findings-at-ASCO.jpg?resize=525%2C300&ssl=1 1.5x, https:\/\/i0.wp.com\/blogs.cardiff.ac.uk\/centre-for-trials-research\/wp-content\/uploads\/sites\/499\/2023\/11\/Breast-Cancer-Breakthrough-The-FAKTION-Trials-Pioneering-Findings-at-ASCO.jpg?resize=700%2C400&ssl=1 2x, https:\/\/i0.wp.com\/blogs.cardiff.ac.uk\/centre-for-trials-research\/wp-content\/uploads\/sites\/499\/2023\/11\/Breast-Cancer-Breakthrough-The-FAKTION-Trials-Pioneering-Findings-at-ASCO.jpg?resize=1050%2C600&ssl=1 3x, https:\/\/i0.wp.com\/blogs.cardiff.ac.uk\/centre-for-trials-research\/wp-content\/uploads\/sites\/499\/2023\/11\/Breast-Cancer-Breakthrough-The-FAKTION-Trials-Pioneering-Findings-at-ASCO.jpg?resize=1400%2C800&ssl=1 4x"},"classes":[]},{"id":186,"url":"https:\/\/blogs.cardiff.ac.uk\/centre-for-trials-research\/scope2-can-increasing-the-dose-of-radiotherapy-improve-outcomes-in-patients-with-oesophageal-cancer\/","url_meta":{"origin":2941,"position":3},"title":"SCOPE2: Can Increasing The Dose Of Radiotherapy Improve Outcomes In Patients With Oesophageal Cancer?","author":"Ruby Ray","date":"April 26, 2016","format":false,"excerpt":"SCOPE2 is a randomised Phase II\/III trial to study radiotherapy dose escalation in patients with oesophageal cancer treated with definitive chemo-radiation with an embedded Phase II trial for patients with a poor early response using positron emission tomography (PET). SCOPE2\u00a0is a Cancer Research UK\u00a0funded trial run by the Wales Cancer\u2026","rel":"","context":"In "Cancer Trial"","block_context":{"text":"Cancer Trial","link":"https:\/\/blogs.cardiff.ac.uk\/centre-for-trials-research\/category\/cancer-trial\/"},"img":{"alt_text":"SCOPE2 Workshop delegates.","src":"https:\/\/i0.wp.com\/blogs.cardiff.ac.uk\/centre-for-trials-research\/wp-content\/uploads\/sites\/499\/2016\/04\/SCOPE2-Workshop.jpeg?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/blogs.cardiff.ac.uk\/centre-for-trials-research\/wp-content\/uploads\/sites\/499\/2016\/04\/SCOPE2-Workshop.jpeg?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/blogs.cardiff.ac.uk\/centre-for-trials-research\/wp-content\/uploads\/sites\/499\/2016\/04\/SCOPE2-Workshop.jpeg?resize=525%2C300&ssl=1 1.5x, https:\/\/i0.wp.com\/blogs.cardiff.ac.uk\/centre-for-trials-research\/wp-content\/uploads\/sites\/499\/2016\/04\/SCOPE2-Workshop.jpeg?resize=700%2C400&ssl=1 2x"},"classes":[]},{"id":2828,"url":"https:\/\/blogs.cardiff.ac.uk\/centre-for-trials-research\/centre-for-trials-research-at-the-wales-cancer-research-conference-2024\/","url_meta":{"origin":2941,"position":4},"title":"Centre for Trials Research At The Wales Cancer Research Conference 2024","author":"Angela Casbard","date":"March 21, 2024","format":false,"excerpt":"In early March, several Centre for Trials Research (CTR) staff members attended the Wales Cancer Research Conference 2024 at the National Museum, Cardiff. The conference brought together cancer researchers and other stakeholders across Wales and beyond to showcase their research successes and foster new collaborations. Centre for Trials Research Cancer\u2026","rel":"","context":"In "Events"","block_context":{"text":"Events","link":"https:\/\/blogs.cardiff.ac.uk\/centre-for-trials-research\/category\/events\/"},"img":{"alt_text":"Cancer Division Photo at the Wales Cancer Centre Conference in March 2024.","src":"https:\/\/i0.wp.com\/blogs.cardiff.ac.uk\/centre-for-trials-research\/wp-content\/uploads\/sites\/499\/2024\/03\/WCC1-scaled.jpg?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/blogs.cardiff.ac.uk\/centre-for-trials-research\/wp-content\/uploads\/sites\/499\/2024\/03\/WCC1-scaled.jpg?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/blogs.cardiff.ac.uk\/centre-for-trials-research\/wp-content\/uploads\/sites\/499\/2024\/03\/WCC1-scaled.jpg?resize=525%2C300&ssl=1 1.5x, https:\/\/i0.wp.com\/blogs.cardiff.ac.uk\/centre-for-trials-research\/wp-content\/uploads\/sites\/499\/2024\/03\/WCC1-scaled.jpg?resize=700%2C400&ssl=1 2x, https:\/\/i0.wp.com\/blogs.cardiff.ac.uk\/centre-for-trials-research\/wp-content\/uploads\/sites\/499\/2024\/03\/WCC1-scaled.jpg?resize=1050%2C600&ssl=1 3x, https:\/\/i0.wp.com\/blogs.cardiff.ac.uk\/centre-for-trials-research\/wp-content\/uploads\/sites\/499\/2024\/03\/WCC1-scaled.jpg?resize=1400%2C800&ssl=1 4x"},"classes":[]},{"id":152,"url":"https:\/\/blogs.cardiff.ac.uk\/centre-for-trials-research\/pin-a-trial-looking-at-olaparib-for-non-small-cell-lung-cancer\/","url_meta":{"origin":2941,"position":5},"title":"PIN: A Trial Looking At Olaparib For Non Small Cell Lung Cancer","author":"Joanna Canham","date":"April 13, 2016","format":false,"excerpt":"In 2013, there were 45,525 new cases of lung cancer in the UK and it kills around 35,000 annually (Source: CRUK). Non-small cell lung cancer (NSCLC) accounts for around 87% of all lung cancer. NSCLC is one of the leading causes of death worldwide and presents a huge health economic\u2026","rel":"","context":"In "Cancer Trial"","block_context":{"text":"Cancer Trial","link":"https:\/\/blogs.cardiff.ac.uk\/centre-for-trials-research\/category\/cancer-trial\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/blogs.cardiff.ac.uk\/centre-for-trials-research\/wp-content\/uploads\/sites\/499\/2016\/04\/030914_7508-scaled.jpg?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/blogs.cardiff.ac.uk\/centre-for-trials-research\/wp-content\/uploads\/sites\/499\/2016\/04\/030914_7508-scaled.jpg?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/blogs.cardiff.ac.uk\/centre-for-trials-research\/wp-content\/uploads\/sites\/499\/2016\/04\/030914_7508-scaled.jpg?resize=525%2C300&ssl=1 1.5x, https:\/\/i0.wp.com\/blogs.cardiff.ac.uk\/centre-for-trials-research\/wp-content\/uploads\/sites\/499\/2016\/04\/030914_7508-scaled.jpg?resize=700%2C400&ssl=1 2x, https:\/\/i0.wp.com\/blogs.cardiff.ac.uk\/centre-for-trials-research\/wp-content\/uploads\/sites\/499\/2016\/04\/030914_7508-scaled.jpg?resize=1050%2C600&ssl=1 3x, https:\/\/i0.wp.com\/blogs.cardiff.ac.uk\/centre-for-trials-research\/wp-content\/uploads\/sites\/499\/2016\/04\/030914_7508-scaled.jpg?resize=1400%2C800&ssl=1 4x"},"classes":[]}],"meta_box":[],"jetpack_featured_media_url":"","_links":{"self":[{"href":"https:\/\/blogs.cardiff.ac.uk\/centre-for-trials-research\/wp-json\/wp\/v2\/posts\/2941","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/blogs.cardiff.ac.uk\/centre-for-trials-research\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/blogs.cardiff.ac.uk\/centre-for-trials-research\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/blogs.cardiff.ac.uk\/centre-for-trials-research\/wp-json\/wp\/v2\/users\/7068"}],"replies":[{"embeddable":true,"href":"https:\/\/blogs.cardiff.ac.uk\/centre-for-trials-research\/wp-json\/wp\/v2\/comments?post=2941"}],"version-history":[{"count":1,"href":"https:\/\/blogs.cardiff.ac.uk\/centre-for-trials-research\/wp-json\/wp\/v2\/posts\/2941\/revisions"}],"predecessor-version":[{"id":2944,"href":"https:\/\/blogs.cardiff.ac.uk\/centre-for-trials-research\/wp-json\/wp\/v2\/posts\/2941\/revisions\/2944"}],"wp:attachment":[{"href":"https:\/\/blogs.cardiff.ac.uk\/centre-for-trials-research\/wp-json\/wp\/v2\/media?parent=2941"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/blogs.cardiff.ac.uk\/centre-for-trials-research\/wp-json\/wp\/v2\/categories?post=2941"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/blogs.cardiff.ac.uk\/centre-for-trials-research\/wp-json\/wp\/v2\/tags?post=2941"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}